Tag: Ophthalmology
PharmaSignal — Ophthalmology
MSD-backed Ray locks in $125m to back eye drug pipeline
Pharmaceutical Technology
Ray’s MSD and Novo Holdings-backed Series B will shed light on the potential of the company’s vision restoration gene therapy pipeline.
FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)
Big Molecule Watch
On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.
Senju launches first-in-class dry eye disease drug in Japan
Pharmaphorum
Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
PharmaTimes
Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3
BioSpace
Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.
Amgen scores with new thyroid eye disease formulation
Pharmaphorum
Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
Viridian tumbles on positive data for key eye drug prospect
BioPharma Dive
The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.